ArticleSystematic reviews2026
Safety, immunogenicity, efficacy, and effectiveness of mpox vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis.
Article in Systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundMpox is a zoonotic disease caused by the monkeypox virus (MPXV) that became a global health concern following the 2022 outbreak. It poses a significant threat to immunocompromised individuals, children, and pregnant persons. Disease spread in the Democratic Republic of the Congo (DRC) and propagation to other countries has led to recent declarations of public health emergencies. Smallpox vaccination cessation has further heightened population vulnerability to MPXV. In response, MVA-BN and LC16m8, vaccinia-based vaccines originally developed for smallpox, have been repurposed for mpox, demonstrating promising safety and immunogenicity profiles. Despite these advancements, challenges remain in vaccine distribution and in understanding vaccine efficacy across populations, particularly in key at-risk groups. Available evidence remains fragmented and largely derived from adult populations, with limited data in pregnant persons, children, and adolescents. This living systematic review (LSR) aims to evaluate the safety, efficacy, effectiveness, and immunogenicity of mpox vaccines across populations, with particular focus on pregnant persons, children, and adolescents.
methodsWe aim to conduct a LSR and meta-analysis based on biweekly searches of medical databases and clinical trial registries from inception to the current date to systematically identify relevant studies of mpox vaccines across populations. Pairs of reviewers will independently select eligible studies, extract data, and assess the risk of bias. We will include randomized clinical trials, quasi-experimental studies, cohort studies, case-control studies, cross-sectional studies, and case reports. Primary outcomes will include safety, efficacy/effectiveness, and immunogenicity of mpox vaccines across populations, including outcomes in pregnant persons (with neonatal outcomes), children, and adolescents. Meta-analyses will be conducted, including prespecified subgroup and sensitivity analyses. We will use the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence. DISCUSSION: This LSR will synthesize evidence on mpox vaccines across populations, with particular focus on pregnant persons, children, and adolescents. As mpox continues to pose a global threat, particularly in endemic and low-resource settings, timely and rigorous assessment of vaccine performance is essential to guide equitable immunization policies and maternal-child health strategies. SYSTEMATIC REVIEW REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO): CRD42024554330 (pregnant persons) and CRD42024556977 (children and adolescents).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.